# Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma

> **NCT00075946** · PHASE3 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 545 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00075946
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-23
- **Primary completion:** 2013-09
- **Final completion:** 2021-08
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075946, "Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00075946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*